Physician profile
Ness Rells
NPI 1114646973
$8,791.24
in general payments reported to CMS, 2019-2025
40 companies · $3,144 in 2025
The $3,144 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,000 · 2023: $2,027 · 2024: $2,620 · 2025: $3,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,465 · Travel and Lodging: $300 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,465.35 |
| Travel and Lodging | $300.44 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,450.66 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Cvrx, INC. | $1,414.37 | 2023-2025 | Barostim Neo System |
| Cardiva Medical, INC. | $937.29 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Cardiva Vascade 6/7f Vcs |
| Alnylam Pharmaceuticals INC. | $748.96 | 2022-2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $524.28 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $383.25 | 2022-2025 | |
| Boston Scientific Corporation | $263.45 | 2023-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Farapulse |
| Novartis Pharmaceuticals Corporation | $237.08 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $225.01 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.83 | 2023-2024 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $190.24 | 2023-2024 | Inpefa |
| Shockwave Medical, INC | $182.57 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $167.65 | 2024-2025 | |
| Amgen INC. | $159.86 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $154.73 | 2022-2024 | Xarelto |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $149.35 | 2022-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $144.49 | 2023-2024 | Brilinta, Farxiga |
| Scpharmaceuticals INC. | $141.18 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $124.38 | 2024 | Arcalyst |
| Medtronic, INC. | $119.67 | 2022-2023 | Linq II |
| Pfizer INC. | $109.40 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $109.01 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $86.06 | 2022-2024 | Nexletol |
| Stryker Corporation | $73.24 | 2025 | Flowtriever, Artix Mt |
| E.R. Squibb & Sons, L.L.C. | $70.16 | 2022-2025 | Eliquis |
| Abiomed | $48.23 | 2023-2025 | Impella |
| Chiesi USA, INC. | $47.42 | 2022-2024 | Juxtapid |
| Bard Peripheral Vascular, INC. | $44.63 | 2023 | Venclose Maven Catheter |
| Kiniksa Pharmaceuticals, Ltd. | $41.60 | 2022-2023 | Arcalyst |
| Tactile Systems Technology INC | $38.47 | 2025 | Flexitouch Plus, Nimbl |
| Recor Medical INC | $33.02 | 2025 | Paradise Ultrasound Renal Denervation System |
| Glaxosmithkline, LLC. | $26.49 | 2025 | Shingrix |
| Lilly USA, LLC | $25.71 | 2025 | Zepbound |
| Davol INC. | $24.47 | 2024 | |
| Irhythm Technologies, INC. | $22.99 | 2024 | Zio Monitor, Zio Xt Patch |
| Bolton Medical INC | $18.47 | 2023 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Actelion Pharmaceuticals US, INC. | $15.81 | 2025 | Opsynvi, Uptravi |
| Itamar Medical INC | $14.67 | 2022 | |
| Amryt Pharma Holdings Ltd | $14.60 | 2023 | Juxtapid |
| Daiichi Sankyo INC. | $13.49 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ness Rells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.